Joe Y Chang, MD, PhD · @JoeChangMD“I am pleased to share the results of our phase II randomized I-SABR study @ASTRO_org 2026 which demonstrate improved overall survival (OS) when adding four doses of immunotherapy to SABR in early-stage NSCLC. These exciting findings are associated with the persistent activation of cytotoxic T cells for up to 6.5 years. Further optimization of I-SABR approaches will guide future research and clinical practice.”
View post ↗More lung cancer trial coverage on KOL Pulse →The phase II I-SABR study demonstrated improved overall survival from adding immunotherapy to SABR in early-stage NSCLC, a finding Dr. Joe Y Chang links to persistent cytotoxic T cell activation. In regulatory news, the Biologics License Application for the investigational agent ifinatamab deruxtecan was voluntarily withdrawn for extensive-stage SCLC after phase II IDeate-Lung01 data did not meet requirements for accelerated approval. Additionally, a new observational study on the investigational BiTE tarlatamab found that concomitant use of common medications, particularly antibiotics, was linked to worse overall survival in patients with ES-SCLC. In deal news, AstraZeneca is partnering with Summit Therapeutics to co-develop the VEGF/PD-1 bispecific ivonescimab, with a particular focus on ADC combinations.
“I am pleased to share the results of our phase II randomized I-SABR study @ASTRO_org 2026 which demonstrate improved overall survival (OS) when adding four doses of immunotherapy to SABR in early-stage NSCLC.”
— @JoeChangMD · I-SABR in early-stage NSCLC · View post ↗📌 Amplified by @KolPulseAI
“🔥IDeate-Lung01: "Data do not satisfy requirements needed to support an accelerated approval — BLA voluntarily withdrawn"”
— @HHorinouchi · Ifinatamab deruxtecan BLA withdrawal · View post ↗📌 Amplified by @KolPulseAI
“➡️ In patients on tarlatamab for ES-SCLC, 5 common drug classes were linked to worse overall survival.”
— @LauraAlderMD · Tarlatamab and concomitant medications · View post ↗
“Helpful review and meta-analysis of HER2 directed therapies for NSCLC including TKIs and ADCs @JTOonline. Suggests preference for TKIs over ADCs given high RR (particularly in YVMA insertion) and safety.”
— @StephenVLiu · HER2-directed therapies in NSCLC · View post ↗
“What strikes me most as a simple.medonc is the accumulating evidence that SBRT is matching surgery in more and more settings: early lung cancer, localized prostate (PACE-A data here this week), selected oligometastases, small HCC.”
— @StrijbosMichiel · SBRT vs. Surgery · View post ↗📌 Amplified by @KolPulseAI
“AZ are linking with Summit Therapeutics to develop Ivonescimab (VEGF/PD1 bispecific), particularly ADC combos. This promising area of development is moving rapidly. This link will accelerate things further. Robust global data outside of lung cancer is eagerly awaited.”
— @tompowles1 · AstraZeneca-Summit Therapeutics Ivonescimab deal · View post ↗A multicenter Italian study of 302 patients with male breast cancer found radiation therapy was associated with improved survival in advanced-stage disease, with a low incidence of late adverse events across the 10-center cohort. Looking ahead, previews of the ESMO 2026 breast cancer programme are circulating, spotlighting six-year survival follow-up for NATALEE, final neoadjuvant T-DXd results from TALENT in HER2-low HR+ early breast cancer, and new endocrine-resistance approaches (FINER, VIKTORIA-1, postMONARCH, evERA) after CDK4/6 inhibition.
“Radiation therapy and overall survival in male breast cancer: a multicenter analysis of 302 patients Proud to share our multicenter study on male breast cancer 302 patients across 10 Italian centers Favorable outcomes with multimodality treatment Radiation therapy was associated with improved survival in advanced-stage disease low incidence of late adverse events, further supporting its role in clinical practice.”
— @to_be_elizabeth · Radiotherapy in male breast cancer · View post ↗
“European Society for Medical Oncology 2026 may be as much about treatment sequencing as it is about new drugs. The upcoming breast cancer programme brings together several important clinical questions across early and metastatic disease. NATALEE reaches six-year survival follow-up. TALENT reports final neoadjuvant T-DXd results in HER2-low, HR-positive early breast cancer. KEYNOTE-B49 tests checkpoint inhibition in advanced HR-positive/HER2-negative disease.”
— @OncoDailyBreast · ESMO 2026 breast programme preview · View post ↗At ASTRO 2026, Ted Hong presented NRG-GI003 results comparing photon and proton radiotherapy in hepatocellular carcinoma, testing the hypothesis that protons could reduce liver decompensation and improve the primary endpoint of overall survival, building on prior work from the Sanford group. Separately, Erika Ruiz highlighted daraxonrasib data in previously treated metastatic pancreatic adenocarcinoma, reporting promising survival and response results building on earlier ASCO findings.
“Next up, Team GI’s @TedHong9 discussing NRG-GI003 results of photons vs protons for HCC! Hypothesis: protons could reduce liver decomp and improve OS, the primary endpoint. This was based on data from preceding work published by @NiuSanford , showing potential gains with protons”
— @lauren_henke · NRG-GI003: protons vs. photons in HCC · View post ↗
“A source of pride for Mexico and Ibero-America. We are delighted to have Dr. Erika Ruiz representing ASCO at ASTRO 2026. In her talk, she shared advances presented at ASCO on daraxonrasib for previously treated metastatic pancreatic adenocarcinoma, including promising survival and response results”
— @ArmandoFelix70 · Daraxonrasib in metastatic pancreatic cancer · View post ↗Track oncology’s top KOLs in your specialty
Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
- ✓Enhanced KOL profiles
- ✓Pharma influence & potential advisory-board patterns
- ✓2025 Open Payments financial analysis
- ✓Social-media sentiment & trend signals
The European Society for Medical Oncology (ESMO) released updated clinical practice guidelines for advanced and metastatic prostate cancer. In imaging, a PSMA PET/CT radiomics study identified a 9-feature risk score that stratified patients for biochemical recurrence and distant metastasis. A safety analysis of Lu-177-PSMA radioligand therapy found that close sequencing with spine radiotherapy was not associated with severe RT-site toxicity, though grade ≥3 hematologic adverse events occurred in 33% of patients.
“🗣️ The updated @myESMO guidelines for advanced and metastatic #ProstateCancer are a pleasure to read.”
— @drenriquegrande · ESMO Prostate Cancer Guidelines · View post ↗
“🧬 This is where molecular imaging starts to become a treatment-planning tool — not just a diagnostic one.”
— @nataliagandur · CAIX PET/CT in RCC · View post ↗
“🔑Closely sequenced spine RT + Lu-177-PSMA RLT was not associated with observed severe RT-site toxicity during available follow-up; association with total RLT cycles is exploratory”
— @RKSayyid · Lu-177-PSMA and Spine RT Safety · View post ↗
“Please do not radiate a patient with a peak flow <10 mL/s or PVR >150 mL without having them evaluated by a non-oncologic urologist first.”
— @JoelHillelsohn · Prostate Radiotherapy Safety · View post ↗A large, multicenter real-world study from USMIRC comparing first BCMA-directed therapies found a higher overall response rate with CAR-T (87%) versus teclistamab (68%). Separately, the phase 3 EXCALIBER-RRMM trial showed the investigational agent iberdomide with daratumumab/dexamethasone achieved a higher MRD negativity rate (41% vs. 21%) than daratumumab/bortezomib/dexamethasone, though with more grade 3-4 adverse events.
“Overall response rate was 87% with CAR-T versus 68% with teclistamab. 📊”
— @Abdallah81MD · Real-World BCMA Therapy Comparison · View post ↗📌 Amplified by @KolPulseAI
“EXCALIBER-RRMM phase 3 of iberdomide/dara/dex vs dara/bortez/dex shows (median follow-up 15.7 mos) MRD- CR in 85 (41%) vs. 44 (21%)”
— @Myeloma_Doc · EXCALIBER-RRMM Trial · View post ↗📌 Amplified by @KolPulseAI
“A disease still killing more than 10,000 Americans every year is not a field ready for a victory lap—or reduced R&D investment. #MultipleMyeloma #MMSM #HemeTwitter”
— @HenrychihangFu1 · Myeloma Research Funding · View post ↗“Phase 2 IZALCO study in RRMM w/ sc isatuximab via on-body injector versus manual injection finds both patients (74.5% (35/47)) and HCPs (78.9% (15/19)) prefer the OBI to sc manual injection”
— @Myeloma_Doc · Isatuximab On-Body Injector · View post ↗An exploratory study in advanced hematologic malignancies found baseline vitality (SF-36) was associated with survival beyond ECOG performance status, with low vitality linked to 60% mortality versus 29% for high vitality. Separately, the phase I HyDEF trial is evaluating a novel radiotherapy fractionation schedule as a bridge to CAR-T in diffuse large B-cell lymphoma; the first patient treated showed a 98% tumor volume reduction by day 60.
“If we treat cancer, we should also measure vitality. Not instead of ECOG. Beyond it. Because the goal is not only to know how the disease is doing. It is to know how the person is still standing.”
— @HumbertoMar_Cor · Vitality as a prognostic factor · View post ↗
“The protocol treats two halves of the same tumor with radiobiologically equivalent but different fractionated doses, enabling a direct intra-tumoral comparison of fractionation schedules in patients with diffuse large B-cell lymphoma bridging to CAR-T therapy.”
— @YaleCancer · HyDEF trial · View post ↗
“We just reported our experience with steroid or anakinra prophylaxis in patients with high ferritin/CRP receiving axi-cel for DLBCL 1/n”
— @MichaelDJain · CAR-T toxicity prophylaxis · View post ↗“In a study of 142 adults undergoing allogeneic stem cell transplant for ALL or AML, TBI with lung shielding yielded a 13.4% rate of severe pulmonary toxicity, with no cases attributed to radiation pneumonitis.”
— @YaleCancer · Total Body Irradiation safety · View post ↗